Sapien 3 TAVR offers improved outcomes, reduced cost, Edwards Lifesciences says

Edwards-Commander — Edwards Lifesciences created its Commander delivery system for its Sapien 3 TAVR. [Image courtesy of Edwards]

Edwards Lifesciences (NYSE:EW) today touted a cost-effectiveness analysis that supports transcatheter aortic valve replacement (TAVR) with the Sapien 3.

Irvine, California-based Edwards presented data from the Partner 3 trial during the late-breaking clinical trials at the 33rd Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation.

Get the full story on our sister site MassDevice.